In an exploratory analysis of 39 patients who provided tumor samples for analysis of DLL3 expression, 29 assessable patients had DLL3-high tumors (defined as expression in 50% or more tumor cells by IHC), and 10 (35%) of these patients had a confirmed objective response. This evidence concerns the gene DLL3 and neoplasm.